The FDA assigns a Fast Track status to AstraZeneca's (AZN) Farxiga to reduce the risk of cardiovascular death or worsening of heart failure in adult patients with HFrEF and HFpEF.
source https://finance.yahoo.com/news/astrazenecas-farxiga-gets-fast-track-144302314.html?.tsrc=rss
blaineonline.finance.blog 